中国药业2024，Vol.33Issue(8)：9-13,5.DOI:10.3969/j.issn.1006-4931.2024.08.003
临床药师干预伏立康唑不良潜在药物相互作用实践效果
Effect Analysis of Clinical Pharmacists' Intervention on Adverse Potential Drug-Drug Interactions of Voriconazole
摘要
Abstract
Objective To promote the rational use of voriconazole in clinical practice.Methods A catalogue for drug combination classification related to adverse potential drug-drug interactions(pDDIs)of voriconazole in the hospital was formulated.Clinical pharmacists summarized the risks and medication recommendations for voriconazole-related pDDIs based on pharmacological effects,carried out special training on rational use of voriconazole in clinical departments and real-time intervention on medical orders(prescriptions)through the pre-review prescription system,and provided individualized and refined medication reminder information.The patients treated with voriconazole discharged from the Anhui Chest Hospital from January 1 to March 31,2021(before intervention)and from January 1 to March 31,2023(after intervention)were selected as the control group(186 cases)and the intervention group(140 cases)respectively by the PASS prescription review system of the PIP Platform.The related information of patients were collected,the incidence of voriconazole-related adverse pDDIs and adverse drug reactions(ADRs)was analyzed.Results There were 80 cases(57.14%)and 101 case times of voriconazole-related pDDIs in the intervention group,which were significantly less than 123 cases(66.13%)and 181 case times in the control group(P<0.05).Compared with that in the control group,the frequency proportion of adverse pDDIs induced by the combination of voriconazole with omeprazole,dexamethasone,rifampicin and simvastatin in the intervention group decreased.The incidence of ADRs was 6.43%in the intervention group,which was lower than 10.22%in the control group(P>0.05);the incidence of voriconazole-related pDDIs was 88.89%,which was slightly lower than 89.47%in the control group(P>0.05);the incidence of severe ADRs was 11.11%,which was significantly lower than 52.63%in the control group(P<0.05);the proportion of patients having voriconazole-related adverse pDDIs(twice or more)and ADRs was 44.44%,which was lower than 36.84%in the control group(P>0.05).Conclusion There are multiple adverse pDDIs between voriconazole and various drugs.Clinical pharmacists' practice in the rational medication training and prescription intervention can decrease the medication risk and ensure the patients' medication safety.关键词
伏立康唑/不良潜在药物相互作用/临床药师/处方审核/合理用药Key words
voriconazole/adverse potential drug-drug interaction/clinical pharmacist/prescription review/rational drug use分类
医药卫生引用本文复制引用
丁海华,陈道俊,王华,张云玲..临床药师干预伏立康唑不良潜在药物相互作用实践效果[J].中国药业,2024,33(8):9-13,5.基金项目
安徽省卫生健康科研项目[AHWJ2022b040]. （）
